查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2030033

標靶癌症治療市場－全球產業規模、佔有率、趨勢、機會和預測：按治療類型、疾病適應症、最終用戶、地區和競爭格局分類，2021-2031年

Targeted Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapy Type, By Disease Indication, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球標靶癌症療法市場預計將從 2025 年的 168.2 億美元成長到 2031 年的 262.6 億美元，複合年成長率為 7.71%。

這種精準醫療策略著重於利用癌細胞獨特的分子特徵來識別並選擇性地靶向癌細胞，從而幫助減輕對健康組織的繼發性損傷。市場成長主要受全球癌症發病率上升、基因組學和生物標記發現的重大進展以及對高效個性化治療方法日益成長的需求所驅動。

市場概覽
預測期 2027-2031
市場規模：2025年 168.2億美元
市場規模：2031年 262.6億美元
複合年成長率：2026-2031年 7.71%
成長最快的細分市場 乳癌
最大的市場 北美洲

美國藥品研究與製造商協會 (PhRMA) 的 2025 年年度報告強調了該領域的持續創新，指出 2025 年共批准了 14 項與腫瘤相關的核准，其中包括標靶治療。儘管取得了這些進展，但由於開發和商業化這些先進治療方法的高昂成本，以及嚴格的法規結構延長了新療法上市所需的時間，市場成長受到了顯著阻礙。

市場促進因素

標靶癌症治療市場的主要促進因素是全球癌症發生率和整體負擔的不斷上升。隨著國際診斷病例的增加，對先進且高效治療方法的需求日益成長，推動了精準醫療的研發和應用。根據發表在2025年9月《採血針》雜誌上的一項研究，2023年全球新增癌症病例超過1,800萬例。這一成長趨勢要求腫瘤學領域持續取得進展，而標靶治療有望透過直接針對疾病的分子機制來改善患者的治療效果。需要治療的患者群體不斷擴大，凸顯了該領域對醫學突破的持續需求。

此外，基因組研究和精準醫療的突破也在推動市場成長。對癌症分子基礎的深入了解有助於識別特定的基因突變和生物標記物，從而開發高度個人化的治療方法。企業的巨額資金投入進一步增強了這一發展勢頭。例如，諾華公司於2025年4月宣布了一項計劃，將在未來五年內投資230億美元用於美國的基礎設施建設，並擴大其研發能力，尤其是在癌症治療領域。這些資金投入將促進新型標靶治療的臨床應用和研發，進而重振整個腫瘤製藥產業。例如，根據《製藥技術》雜誌2026年2月報道，葛蘭素史克（GSK）的腫瘤部門在2025會計年度的銷售額成長了43%，達到近20億英鎊。

市場挑戰

全球市場擴張的一大障礙是標靶癌症療法研發和商業化過程中巨大的資金負擔。精準的分子標靶識別、新型化合物設計以及全面的臨床前和臨床評估都涉及複雜的研發流程，需要大量資金投入。此類創新的高昂成本直接影響這些療法的定價模式，可能限制其在各種醫療保健網路中的普及和整合。

進一步加劇這些財務壓力的還有嚴格的監管程序，這些程序延長了產品上市時間，使整體挑戰更加艱鉅。在極其有限的患者群體中證明療效和安全性的嚴格要求，往往導致臨床試驗階段延長，並需要收集大量數據。根據國際藥品製造商協會聯合會（IFPMA）的數據，2019年至2023年間，從臨床試驗開始到完成患者招募的平均時間增加了26%。這種時間的延長不僅推高了研發成本，還延遲了製藥公司的獲利，並最終限制了未來用於發現新型標靶治療的資金投入。

市場趨勢

人工智慧 (AI) 的應用正在改變標靶治療領域，加速診斷方法的開發和新藥的發現。 AI 系統能夠透過評估龐大的蛋白質體學和基因組學資料集，更準確地識別新的治療標靶並預測患者的治療反應，從而簡化初步研究。這項技術的引入有助於最佳化化合物設計，降低上市成本並縮短上市時間。根據《富比士》2026 年 3 月的一篇報導，羅氏公司投資約 6,500 萬至 8,700 萬美元購買英偉達 Blackwell GPU，以建立大規模AI 設施，加速新診斷方法和藥物的開發。這凸顯了該產業致力於利用 AI 來簡化整個治療藥物開發流程的決心。

另一個值得關注的趨勢是新一代標靶治療的興起。這些療法超越了傳統的抗體和小分子藥物，採用了更精密的先進技術。這些先進治療方法包括新型偶聯物平台、基因療法和複雜的細胞療法，旨在為以往難以治療的癌症提供更卓越的療效和更精準的治療。這些突破性的進展旨在克服治療抗藥性，並滿足病患小組未被滿足的醫療需求。例如，BioPharma Dive在2026年4月報道稱，禮來公司已同意以高達70億美元的價格收購Kelonia Therapeutics公司，其中包括32.5億美元的首付款，以獲得用於體內CAR-T細胞工程的iGPS技術。此次收購凸顯了癌症治療產業轉型為創新治療方法策略的趨勢。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球標靶癌症治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（荷爾蒙療法、單株抗體、訊號路徑抑制劑、基因表現調節劑、細胞凋亡抑制劑等）
    • 特定疾病（肺癌、乳癌、大腸癌、白血病、惡性黑色素瘤、淋巴瘤、其他）
    • 依最終使用者（醫院/診所、癌症/放射治療中心、學術/研究機構）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美標靶癌症療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲標靶癌症療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區標靶癌症療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲標靶癌症療法的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲標靶癌症療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球標靶癌症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson Service Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 8113

The Global targeted cancer therapy market is anticipated to expand from USD 16.82 billion in 2025 to USD 26.26 billion by 2031, reflecting a compound annual growth rate of 7.71%. This precise medical strategy focuses on identifying and exclusively targeting cancer cells by leveraging their unique molecular traits, which helps reduce collateral damage to healthy tissues. The market's growth is largely fueled by the rising global cancer rate, major breakthroughs in genomics and biomarker discovery, and an escalating need for highly effective, personalized treatment options.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 16.82 Billion
Market Size 2031USD 26.26 Billion
CAGR 2026-20317.71%
Fastest Growing SegmentBreast Cancer
Largest MarketNorth America

Highlighting continuous sector innovation, PhRMA's 2025 Annual Report noted that fourteen oncology approvals, which included targeted therapies, were issued in 2025. Even with these advancements, market growth is significantly hindered by the heavy financial costs tied to the development and commercialization of these sophisticated treatments, as well as strict regulatory frameworks that prolong the time required to bring new therapies to the market.

Market Driver

A major catalyst for the targeted cancer therapy market is the rising global rate and overall burden of cancer. With diagnoses increasing internationally, the need for sophisticated and potent treatment methods escalates, propelling the creation and use of precision medicines. Research featured in The Lancet in September 2025 revealed that more than 18 million new cancer cases were recorded worldwide in 2023. This growing frequency demands relentless progress in oncology, where targeted treatments present the opportunity for better patient results by confronting the underlying molecular causes of the disease. The expanding demographic of patients in need of care highlights a persistent demand for medical breakthroughs in this area.

The market is additionally driven by substantial leaps in genomic research and precision medicine. A more profound comprehension of the molecular foundations of cancer allows for the pinpointing of distinct genetic mutations and biomarkers, which supports the creation of deeply customized therapies. This forward momentum is reinforced by heavy corporate funding, such as Novartis's April 2025 announcement of a projected $23 billion, five-year commitment to US infrastructure, which involves widening its oncology-centered research and development operations. These financial commitments aid the clinical application and discovery of new targeted drugs, thereby boosting the broader oncology pharmaceutical sector. Demonstrating this impact, GSK's oncology sales for the 2025 fiscal year surged by 43% to nearly £2 billion, as reported by Pharmaceutical Technology in February 2026.

Market Challenge

A major obstacle to the expansion of the global market is the massive financial expense linked to the creation and commercial rollout of targeted cancer therapies. Securing precise molecular targets, engineering new compounds, and executing thorough preclinical and clinical evaluations involve complex research and development that requires immense capital. The steep price of such innovation directly affects the pricing models of these treatments, which can subsequently restrict their availability and integration within various healthcare networks.

Compounding these financial pressures are rigorous regulatory procedures that lengthen the timeframe for bringing products to market, intensifying the overall challenge. Strict mandates to prove effectiveness and safety among highly narrow patient demographics frequently lead to extended clinical testing stages and voluminous data requirements. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) noted that the typical duration from the initiation of a clinical trial to the conclusion of patient enrollment grew by 26% between 2019 and 2023. Such extended timelines not only drive up R&D costs but also postpone the financial returns for pharmaceutical firms, ultimately limiting future capital allocation toward the discovery of new targeted therapies.

Market Trends

The incorporation of artificial intelligence is transforming the targeted cancer therapy sector by speeding up the creation of diagnostics and the discovery of new drugs. By evaluating massive proteomic and genomic datasets, AI systems can pinpoint new therapeutic targets and forecast patient reactions with heightened accuracy, thereby simplifying preliminary research. This technological adoption aids in reducing the expenses and timeframes linked to market introductions by refining the design of compounds. As reported by Forbes in March 2026, Roche established a massive AI facility, investing an estimated $65 million to $87 million in Nvidia Blackwell GPUs to hasten the creation of fresh diagnostics and medications, underscoring the sector's dedication to using AI to improve efficiency throughout the treatment development process.

Another prominent trend is the rise of next-generation targeted treatments, which expand past conventional antibodies and small molecules to include more sophisticated methods. These advanced modalities encompass novel conjugate platforms, gene therapies, and complex cell therapies designed to deliver superior effectiveness and precision against historically untreatable cancers. Such breakthroughs are intended to conquer treatment resistance and fulfill unaddressed requirements within patient groups. For example, BioPharma Dive reported in April 2026 that Eli Lilly arranged to purchase Kelonia Therapeutics for as much as $7 billion, including a $3.25 billion initial payment, to acquire its iGPS technology for in vivo CAR-T cell engineering. This purchase highlights a strategic industry pivot toward revolutionary treatment methodologies in cancer care.

Key Market Players

  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson Service Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.

Report Scope

In this report, the Global Targeted Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Targeted Cancer Therapy Market, By Therapy Type

  • Hormone Therapies
  • Monoclonal Antibodies
  • Signal Transduction Inhibitors
  • Gene Expression Modulators
  • Apoptosis Inhibitors
  • Others

Targeted Cancer Therapy Market, By Disease Indication

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Melanoma
  • Lymphoma
  • Others

Targeted Cancer Therapy Market, By End User

  • Hospitals & Clinics
  • Cancer & Radiation Therapy Centers
  • Academic & Research Institutions

Targeted Cancer Therapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Targeted Cancer Therapy Market.

Available Customizations:

Global Targeted Cancer Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Targeted Cancer Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Hormone Therapies, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors, Others)
    • 5.2.2. By Disease Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Lymphoma, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Cancer & Radiation Therapy Centers, Academic & Research Institutions)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Targeted Cancer Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By Disease Indication
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Targeted Cancer Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By Disease Indication
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Targeted Cancer Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By Disease Indication
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Targeted Cancer Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By Disease Indication
        • 6.3.3.2.3. By End User

7. Europe Targeted Cancer Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By Disease Indication
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Targeted Cancer Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By Disease Indication
        • 7.3.1.2.3. By End User
    • 7.3.2. France Targeted Cancer Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By Disease Indication
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Targeted Cancer Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By Disease Indication
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Targeted Cancer Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By Disease Indication
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Targeted Cancer Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By Disease Indication
        • 7.3.5.2.3. By End User

8. Asia Pacific Targeted Cancer Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By Disease Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Targeted Cancer Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By Disease Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. India Targeted Cancer Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By Disease Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Targeted Cancer Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By Disease Indication
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Targeted Cancer Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By Disease Indication
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Targeted Cancer Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By Disease Indication
        • 8.3.5.2.3. By End User

9. Middle East & Africa Targeted Cancer Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By Disease Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Targeted Cancer Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By Disease Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Targeted Cancer Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By Disease Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Targeted Cancer Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By Disease Indication
        • 9.3.3.2.3. By End User

10. South America Targeted Cancer Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By Disease Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Targeted Cancer Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By Disease Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Targeted Cancer Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By Disease Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Targeted Cancer Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By Disease Indication
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Targeted Cancer Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Amgen Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AstraZeneca plc
  • 15.3. Bayer AG
  • 15.4. Bristol-Myers Squibb Company
  • 15.5. F. Hoffmann-La Roche Ltd
  • 15.6. GlaxoSmithKline plc
  • 15.7. Johnson & Johnson Service Inc.
  • 15.8. Merck & Co. Inc.
  • 15.9. Novartis AG
  • 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer